Mike Hollan

Ex-Wall Street trader is helping reshape how patients receive biologics.

A mission leader in next-generation pursuits around targeted therapy.

Pioneer of cell-reset technology steers science-to-startup transformation.

The comments came after the AAP announced its vaccine recommendations, which go against those of the CDC.

The move is likely part of the company’s goal to reduce costs as it faces increased competition in the GLP-1 space.

The EMD Serono president discusses his new role and goals for the company.

EVERSANA’s Alan Crowther discusses how pharma can prepare for the impact of the order.

The disease doesn’t have any FDA approved treatments, leaving families desperate for FDA to approve the treatment.

The AeroRx Therapeutics CEO discusses new treatments and how the industry at large is reacting to them.

The latest decision will give Vanda the opportunity to have a hearing with FDA over the sNDA’s status.

The order aims to set US drug prices at the same level as the lowest cost in other markets.

The Google Cloud director discusses AI implementation and workflow.

The report details the administration’s potential plans for a variety of issues that will directly impact pharma.

The statement appears to be a response to the President’s recent publication of letters to 17 pharma companies about reducing drug prices.

The federally created panel was previously disbanded in 1998.

The new list price will bring the medication in line with other European markets.

Sources say the President’s focus has shifted.

Users find themselves suddenly looking for an extra $500-a-month in their budgets.

Attorney General Paxton argues that the company’s programs and offerings were essentially bribes and resulted in millions in dollars charged to the state’s Medicaid program.

The specialty medication platform earned a spot in the top 15% of the list.

The urology MSO will become part of The Specialty Alliance.

The journal is standing by the study, which looked into the safety of vaccines that have aluminum ingredients.

Secretary Kennedy explained that nearly $500 million in contracts will be canceled.

The talks are a result of the MFN order, which seeks to make US drug prices match lower prices in international markets.

With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?

The industry is facing calls to reduce prices while also bracing for increased tariffs.

The move comes amidst a turbulent time at HHS.

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, high-resolution protein structures, and molecular mechanism of action, as well as optimizing target selection and small molecule design.

Members of the industry believe the US should remain an innovation-friendly market.

Sources also say that the administration plans to split CBER in two, with one of the section focused entirely on vaccines.